Tags

Type your tag names separated by a space and hit enter

Discriminative stimulus effects in rats of SR-141716 (rimonabant), a cannabinoid CB1 receptor antagonist.
Psychopharmacology (Berl). 2004 Dec; 177(1-2):35-45.P

Abstract

OBJECTIVE

To examine the discriminative stimulus effects of (i) the cannabinoid CB(1) receptor antagonist SR-141716 (SR, 5.6 mg/kg) and vehicle, and (ii) the cannabinoid receptor agonist Delta(9)-THC (THC, 1.8 mg/kg) and vehicle using a discriminated taste aversion (DTA) procedure.

METHODS

Two groups of rats (n=6) were trained to discriminate between these drugs and vehicle in DTA (t'=20 min). The 30-min drinking bout of tap water following drug (SR or THC) treatment was followed by an injection of lithium chloride (LiCl, 120 mg/kg) in the experimental animals. When offered water after vehicle pretreatment, experimental animals subsequently were given IP saline (NaCl, 10 ml/kg). Post-drinking treatment for controls (n=6) was NaCl, irrespective of the pretreatment condition (SR, THC or vehicle). Additional water was provided during the afternoon (30 min) with no other manipulations. Food was available ad lib at all times. When the discriminations were established other doses and drugs were examined (t'=20 min). In testing there were no post-drinking treatments.

RESULTS

The SR-related analog AM-251 (dose range: 1-5.6 mg/kg) substituted for SR, whereas other drugs such as the cannabinoid CB(2) receptor antagonist SR-144528 (3 and 10 mg/kg), THC (1-10 mg/kg), flumazenil (1-10 mg/kg), naloxone (1-10 mg/kg), morphine (10 and 18 mg/kg) and d-amphetamine (1 and 3 mg/kg) did not. There was a dose-related attenuation of SR-induced suppression of drinking when THC (1.8-10 mg/kg) was given together with SR (5.6 mg/kg). In the THC trained rats, SR (1-10 mg/kg), morphine (10 and 18 mg/kg) and d-amphetamine (1 and 3 mg/kg) did not substitute for THC. SR (1 mg/kg) attenuated the THC (1.8 mg/kg) induced suppression of drinking. Together with 3 mg/kg SR and 1.8 mg/kg THC, drinking was roughly equally suppressed in both the experimental group and the controls.

CONCLUSION

SR-141716 induces a discriminative stimulus complex in DTA that shows potential for further examination of cannabinoid receptor antagonism.

Authors+Show Affiliations

Department of Psychology, Temple University, 265-67 Weiss Hall, 1701 North 13th Street, Philadelphia, PA 19122, USA. tjarbe@temple.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

15167981

Citation

Järbe, Torbjörn U C., et al. "Discriminative Stimulus Effects in Rats of SR-141716 (rimonabant), a Cannabinoid CB1 Receptor Antagonist." Psychopharmacology, vol. 177, no. 1-2, 2004, pp. 35-45.
Järbe TU, Harris MY, Li C, et al. Discriminative stimulus effects in rats of SR-141716 (rimonabant), a cannabinoid CB1 receptor antagonist. Psychopharmacology (Berl). 2004;177(1-2):35-45.
Järbe, T. U., Harris, M. Y., Li, C., Liu, Q., & Makriyannis, A. (2004). Discriminative stimulus effects in rats of SR-141716 (rimonabant), a cannabinoid CB1 receptor antagonist. Psychopharmacology, 177(1-2), 35-45.
Järbe TU, et al. Discriminative Stimulus Effects in Rats of SR-141716 (rimonabant), a Cannabinoid CB1 Receptor Antagonist. Psychopharmacology (Berl). 2004;177(1-2):35-45. PubMed PMID: 15167981.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Discriminative stimulus effects in rats of SR-141716 (rimonabant), a cannabinoid CB1 receptor antagonist. AU - Järbe,Torbjörn U C, AU - Harris,Michele Y, AU - Li,Chen, AU - Liu,Qian, AU - Makriyannis,Alexandros, Y1 - 2004/05/27/ PY - 2003/05/13/received PY - 2004/03/27/accepted PY - 2004/5/29/pubmed PY - 2005/3/24/medline PY - 2004/5/29/entrez SP - 35 EP - 45 JF - Psychopharmacology JO - Psychopharmacology (Berl) VL - 177 IS - 1-2 N2 - OBJECTIVE: To examine the discriminative stimulus effects of (i) the cannabinoid CB(1) receptor antagonist SR-141716 (SR, 5.6 mg/kg) and vehicle, and (ii) the cannabinoid receptor agonist Delta(9)-THC (THC, 1.8 mg/kg) and vehicle using a discriminated taste aversion (DTA) procedure. METHODS: Two groups of rats (n=6) were trained to discriminate between these drugs and vehicle in DTA (t'=20 min). The 30-min drinking bout of tap water following drug (SR or THC) treatment was followed by an injection of lithium chloride (LiCl, 120 mg/kg) in the experimental animals. When offered water after vehicle pretreatment, experimental animals subsequently were given IP saline (NaCl, 10 ml/kg). Post-drinking treatment for controls (n=6) was NaCl, irrespective of the pretreatment condition (SR, THC or vehicle). Additional water was provided during the afternoon (30 min) with no other manipulations. Food was available ad lib at all times. When the discriminations were established other doses and drugs were examined (t'=20 min). In testing there were no post-drinking treatments. RESULTS: The SR-related analog AM-251 (dose range: 1-5.6 mg/kg) substituted for SR, whereas other drugs such as the cannabinoid CB(2) receptor antagonist SR-144528 (3 and 10 mg/kg), THC (1-10 mg/kg), flumazenil (1-10 mg/kg), naloxone (1-10 mg/kg), morphine (10 and 18 mg/kg) and d-amphetamine (1 and 3 mg/kg) did not. There was a dose-related attenuation of SR-induced suppression of drinking when THC (1.8-10 mg/kg) was given together with SR (5.6 mg/kg). In the THC trained rats, SR (1-10 mg/kg), morphine (10 and 18 mg/kg) and d-amphetamine (1 and 3 mg/kg) did not substitute for THC. SR (1 mg/kg) attenuated the THC (1.8 mg/kg) induced suppression of drinking. Together with 3 mg/kg SR and 1.8 mg/kg THC, drinking was roughly equally suppressed in both the experimental group and the controls. CONCLUSION: SR-141716 induces a discriminative stimulus complex in DTA that shows potential for further examination of cannabinoid receptor antagonism. SN - 0033-3158 UR - https://www.unboundmedicine.com/medline/citation/15167981/Discriminative_stimulus_effects_in_rats_of_SR_141716__rimonabant__a_cannabinoid_CB1_receptor_antagonist_ DB - PRIME DP - Unbound Medicine ER -